A Study Comparing the Response of Patients With Hypertension to Amlodipine or Amlodipine Plus Benazepril. - Full Text View

Sponsors and Collaborators:	Novartis Pfizer
Information provided by:	Novartis
ClinicalTrials.gov Identifier:	NCT00171366

Purpose

Comparison of the safety and efficacy of the combination of amlodipine/Benazepril to amlodipine monotherapy in patients with non-essential hypertension, not controlled on amlodipine alone.

Condition	Intervention	Phase
Hypertension	Drug: amlodipine/benazepril	Phase III

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Benazepril hydrochloride Benazepril Amlodipine Amlodipine besylate Lotrel

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Multicenter, Group Study to Evaluate the Safety and Efficacy of Amlodipine and Benazepril Administered in Combination Compared to Amlodipine Monotherapy in Hypertensive Patients Not Adequately Controlled With Amlodipine Alone

Further study details as provided by Novartis:

Primary Outcome Measures:

Change from baseline in mean sitting diastolic blood pressure at week 6

Secondary Outcome Measures:

Change from baseline in mean sitting systolic blood pressure at week 6
Change from week 2 in mean sitting diastolic and systolic blood pressure at week 6
Diastolic response rate at week 6. Patients were considered responders if they had a mean sitting diastolic blood pressure of < 90 mmHg or a >= 10 mm Hg decrease compared to baseline.
Change from baseline in 24 hour diastolic and systolic blood pressure at week 6
Change from baseline in 24 hour diastolic and systolic blood pressure at peak which is defined as the lowest hourly blood pressure mean and the average of the hourly means from 4 to 6 hours post dose at week 6

Estimated Enrollment:	726
Study Start Date:	July 2004

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

Outpatients 18 years of age or older.
Male or female patients are eligible. Female patients must be either post-menopausal for one year or surgically sterile, or using effective, contraceptive methods such as barrier method with spermicide, or an intrauterine device.
Patients with essential hypertension as measured by a validated device

Exclusion Criteria:

Severe hypertension (DBP > 115 mmHg diastolic and/or SBP > 180 mmHg systolic).

Other protocol-defined exclusion criteria may apply.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00171366

Locations

United States, New Jersey
Novartis Pharmaceuticals
E. Hanover, New Jersey, United States, 07936

Sponsors and Collaborators

Novartis

Pfizer

Investigators

Study Director:

Novartis Pharmaceuticals

More Information

No publications provided

Study ID Numbers:	CCIB002H2304
Study First Received:	September 12, 2005
Last Updated:	March 20, 2008
ClinicalTrials.gov Identifier:	NCT00171366 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Novartis:

amlodipine
benazepril
hypertension
diastolic

Study placed in the following topic categories:

Calcium, Dietary
Vasodilator Agents
Benazepril
Vascular Diseases
Angiotensin-Converting Enzyme Inhibitors
Calcium Channel Blockers

Cardiovascular Agents
Antihypertensive Agents
Protease Inhibitors
Amlodipine
Hypertension

Additional relevant MeSH terms:

Vasodilator Agents
Molecular Mechanisms of Pharmacological Action
Vascular Diseases
Calcium Channel Blockers
Enzyme Inhibitors
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions

Protease Inhibitors
Amlodipine
Membrane Transport Modulators
Therapeutic Uses
Benazepril
Angiotensin-Converting Enzyme Inhibitors
Cardiovascular Diseases
Hypertension

ClinicalTrials.gov processed this record on May 06, 2009